NCT01313663 - A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Lung Cancer, Small Cell

Interventions

DRUG

pazopanib

oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance

DRUG

pemetrexed

pemetrexed IV 500 mg/m2 once every 3 weeks

Trial Locations (25)

12110

GSK Investigational Site, Latham

27607

GSK Investigational Site, Raleigh

29425

GSK Investigational Site, Charleston

37421

GSK Investigational Site, Chattanooga

41501

GSK Investigational Site, Pikeville

46219

GSK Investigational Site, Indianapolis

50010

GSK Investigational Site, Ames

58103

GSK Investigational Site, Fargo

60076

GSK Investigational Site, Skokie

60077

GSK Investigational Site, Skokie

65201

GSK Investigational Site, Columbia

66210

GSK Investigational Site, Overland Park

75042

GSK Investigational Site, Garland

75150

GSK Investigational Site, Mesquite

75230

GSK Investigational Site, Dallas

75231

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

75702

GSK Investigational Site, Tyler

76022

GSK Investigational Site, Bedford

77090

GSK Investigational Site, Houston

78666

GSK Investigational Site, San Marcos

85704

GSK Investigational Site, Tucson

89128

GSK Investigational Site, Las Vegas

98201

GSK Investigational Site, Everett

98684

GSK Investigational Site, Vancouver